Secondary Logo

Institutional members access full text with Ovid®

Cell-free Fetal DNA Analysis in Maternal Plasma as Screening Test for Trisomies 21, 18, and 13 in Twin Pregnancy

Le Conte, G.; Letourneau, A.; Jani, J.; Kleinfinger, P.; Lohmann, L.; Costa, J.-M.; Benachi, A.

Obstetrical & Gynecological Survey: February 2019 - Volume 74 - Issue 2 - p 61–63
doi: 10.1097/01.ogx.0000553098.06128.fd

(Abstracted from Ultrasound Obstet Gynecol 2018;52(3):318–324)

Increased use of fertility treatment and advanced maternal age contribute to the increased prevalence of twin pregnancy, which is currently approximately 3% in the United States. Screening for trisomy 21 in twins largely relies on maternal age and nuchal translucency measurement in the first trimester, as well as first- and second-trimester serum screening.

Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart (G.L.C., A.L., A.B.); Université Paris Sud, Kremlin Bicêtre (G.L.C., A.L., A.B.), France; Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium (J.J.); and Laboratoire CERBA, Saint-Ouen l'Aumône, France (P.K., L.L., J.-M.C.)

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.